Cover Image
市場調查報告書

AngioChem Inc. - 產品平台檢討

AngioChem Inc. - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224748
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
AngioChem Inc. - 產品平台檢討 AngioChem Inc. - Product Pipeline Review - 2015
出版日期: 2015年04月15日 內容資訊: 英文 31 Pages
簡介

AngioChem Inc. 是開發以腦疾病為首的腦部相關疾病治療藥之生物科技企業。該公司產品有腫瘤治療藥,胜肽抗體複合體,疼痛治療藥,溶小體儲積症治療藥等。此外為了滿足腦瘤和帕金森氏症,第二型糖尿病,疼痛及其他未滿足需求,該公司也在開發設計通過血腦障壁,獨一無二的治療藥。

本報告提供AngioChem Inc.的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

AngioChem Inc.的基本資料

  • AngioChem Inc.概要
  • 主要資訊
  • 企業資料

AngioChem Inc.:R&D概要

  • 主要的治療範圍

AngioChem Inc.:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品

AngioChem Inc.:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式
    • 藥物研發中的產品/聯合治療模式

AngioChem Inc.:藥物簡介

  • ANG-1005
  • ANG-2002
  • ANG-2004
  • ANG-2008
  • ANG-4043
  • Recombinant Enzyme for Lysosomal Storage Disorder
  • Recombinant Enzyme to Activate Alpha-L-Iduronidase for Mucopolysaccharidosis I

AngioChem Inc.:開發平台分析

  • 按標的
  • 各給藥途徑
  • 各分子類型
  • 各作用機制

AngioChem Inc.:最近的開發平台趨勢

AngioChem Inc.:暫停中的計劃

AngioChem Inc.:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06918CDB

Summary

Global Markets Direct's, 'AngioChem Inc. - Product Pipeline Review - 2015', provides an overview of the AngioChem Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of AngioChem Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of AngioChem Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of AngioChem Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the AngioChem Inc.'s pipeline products

Reasons to buy

  • Evaluate AngioChem Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of AngioChem Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the AngioChem Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of AngioChem Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of AngioChem Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of AngioChem Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • AngioChem Inc. Snapshot
    • AngioChem Inc. Overview
    • Key Information
    • Key Facts
  • AngioChem Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • AngioChem Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • AngioChem Inc. - Pipeline Products Glance
    • AngioChem Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
    • AngioChem Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
      • Discovery Products/Combination Treatment Modalities
  • AngioChem Inc. - Drug Profiles
    • ANG-1005
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANG-2002
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ANG-4043
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate 1 to Target HER2 for Brain Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody Conjugate 2 to Target HER2 for Brain Tumor
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Activate LRP1 for Lysosomal Storage Disorder
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Recombinant Enzyme to Replace Alpha-L-Iduronidase for Mucopolysaccharidosis I
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • AngioChem Inc. - Pipeline Analysis
    • AngioChem Inc. - Pipeline Products by Target
    • AngioChem Inc. - Pipeline Products by Route of Administration
    • AngioChem Inc. - Pipeline Products by Molecule Type
    • AngioChem Inc. - Pipeline Products by Mechanism of Action
  • AngioChem Inc. - Recent Pipeline Updates
  • AngioChem Inc. - Dormant Projects
  • AngioChem Inc. - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • AngioChem Inc., Key Information
  • AngioChem Inc., Key Facts
  • AngioChem Inc. - Pipeline by Indication, 2015
  • AngioChem Inc. - Pipeline by Stage of Development, 2015
  • AngioChem Inc. - Monotherapy Products in Pipeline, 2015
  • AngioChem Inc. - Phase II, 2015
  • AngioChem Inc. - Preclinical, 2015
  • AngioChem Inc. - Discovery, 2015
  • AngioChem Inc. - Pipeline by Target, 2015
  • AngioChem Inc. - Pipeline by Route of Administration, 2015
  • AngioChem Inc. - Pipeline by Molecule Type, 2015
  • AngioChem Inc. - Pipeline Products by Mechanism of Action, 2015
  • AngioChem Inc. - Recent Pipeline Updates, 2015
  • AngioChem Inc. - Dormant Developmental Projects,2015

List of Figures

  • AngioChem Inc. - Pipeline by Top 10 Indication, 2015
  • AngioChem Inc. - Pipeline by Stage of Development, 2015
  • AngioChem Inc. - Monotherapy Products in Pipeline, 2015
  • AngioChem Inc. - Pipeline by Top 10 Target, 2015
  • AngioChem Inc. - Pipeline by Top 10 Molecule Type, 2015
  • AngioChem Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top